PubMed:23321168 JSONTXT

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":58,"end":64},"obj":"gene:57575"},{"id":"T1","span":{"begin":90,"end":104},"obj":"disease:C0005684"},{"id":"T2","span":{"begin":58,"end":64},"obj":"gene:57575"},{"id":"T3","span":{"begin":90,"end":104},"obj":"disease:C0699885"},{"id":"T4","span":{"begin":40,"end":56},"obj":"gene:57575"},{"id":"T5","span":{"begin":90,"end":104},"obj":"disease:C0699885"},{"id":"T6","span":{"begin":40,"end":56},"obj":"gene:57575"},{"id":"T7","span":{"begin":90,"end":104},"obj":"disease:C0005684"},{"id":"T8","span":{"begin":176,"end":192},"obj":"gene:57575"},{"id":"T9","span":{"begin":263,"end":277},"obj":"disease:C0005684"},{"id":"T10","span":{"begin":194,"end":200},"obj":"gene:57575"},{"id":"T11","span":{"begin":263,"end":277},"obj":"disease:C0005684"},{"id":"T12","span":{"begin":194,"end":200},"obj":"gene:57575"},{"id":"T13","span":{"begin":263,"end":277},"obj":"disease:C0699885"},{"id":"T14","span":{"begin":176,"end":192},"obj":"gene:57575"},{"id":"T15","span":{"begin":263,"end":277},"obj":"disease:C0699885"},{"id":"T16","span":{"begin":288,"end":294},"obj":"gene:57575"},{"id":"T17","span":{"begin":639,"end":653},"obj":"disease:C0005684"},{"id":"T18","span":{"begin":288,"end":294},"obj":"gene:57575"},{"id":"T19","span":{"begin":639,"end":653},"obj":"disease:C0699885"},{"id":"T20","span":{"begin":993,"end":999},"obj":"gene:57575"},{"id":"T21","span":{"begin":1104,"end":1118},"obj":"disease:C0699885"},{"id":"T22","span":{"begin":993,"end":999},"obj":"gene:57575"},{"id":"T23","span":{"begin":1104,"end":1118},"obj":"disease:C0005684"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"},{"id":"R6","pred":"associated_with","subj":"T10","obj":"T11"},{"id":"R7","pred":"associated_with","subj":"T12","obj":"T13"},{"id":"R8","pred":"associated_with","subj":"T14","obj":"T15"},{"id":"R9","pred":"associated_with","subj":"T16","obj":"T17"},{"id":"R10","pred":"associated_with","subj":"T18","obj":"T19"},{"id":"R11","pred":"associated_with","subj":"T20","obj":"T21"},{"id":"R12","pred":"associated_with","subj":"T22","obj":"T23"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.\nOBJECTIVE: To investigate the clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in serum-derived DNA from patients with bladder cancer.\nMETHODS: PCDH10 promoter methylation status was determined using methylation-specific polymerase chain reaction of DNA extracted from serum of patients with bladder cancer, and age- and sex-matched controls. Clinical and pathological details of bladder cancer were recorded.\nRESULTS: PCDH10 promoter methylation was detected in 59/117 (50.4%) of patients with bladder cancer, and none of 37 (0%) controls. Methylation was significantly associated with advanced stage (T(2)-T(4)), high grade (G(3)), tumour recurrence and larger tumour size (\u003e 3 cm). In addition, methylation was associated with significantly worse survival and was an independent predictor of overall survival.\nCONCLUSION: Serum-based analysis of PCDH10 promoter methylation may represent a useful noninvasive biomarker of malignant behaviour and outcome in bladder cancer."}

{"project":"Allie","denotations":[{"id":"SS1_23321168_0_0","span":{"begin":176,"end":192},"obj":"expanded"},{"id":"SS2_23321168_0_0","span":{"begin":194,"end":200},"obj":"abbr"},{"id":"SS1_23321168_2_0","span":{"begin":176,"end":192},"obj":"expanded"},{"id":"SS2_23321168_2_0","span":{"begin":194,"end":200},"obj":"abbr"}],"relations":[{"id":"AE1_23321168_0_0","pred":"abbreviatedTo","subj":"SS1_23321168_0_0","obj":"SS2_23321168_0_0"},{"id":"AE1_23321168_2_0","pred":"abbreviatedTo","subj":"SS1_23321168_2_0","obj":"SS2_23321168_2_0"}],"text":"Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.\nOBJECTIVE: To investigate the clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in serum-derived DNA from patients with bladder cancer.\nMETHODS: PCDH10 promoter methylation status was determined using methylation-specific polymerase chain reaction of DNA extracted from serum of patients with bladder cancer, and age- and sex-matched controls. Clinical and pathological details of bladder cancer were recorded.\nRESULTS: PCDH10 promoter methylation was detected in 59/117 (50.4%) of patients with bladder cancer, and none of 37 (0%) controls. Methylation was significantly associated with advanced stage (T(2)-T(4)), high grade (G(3)), tumour recurrence and larger tumour size (\u003e 3 cm). In addition, methylation was associated with significantly worse survival and was an independent predictor of overall survival.\nCONCLUSION: Serum-based analysis of PCDH10 promoter methylation may represent a useful noninvasive biomarker of malignant behaviour and outcome in bladder cancer."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":263,"end":277},"obj":"HP_0009725"},{"id":"T2","span":{"begin":271,"end":277},"obj":"HP_0002664"}],"text":"Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.\nOBJECTIVE: To investigate the clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in serum-derived DNA from patients with bladder cancer.\nMETHODS: PCDH10 promoter methylation status was determined using methylation-specific polymerase chain reaction of DNA extracted from serum of patients with bladder cancer, and age- and sex-matched controls. Clinical and pathological details of bladder cancer were recorded.\nRESULTS: PCDH10 promoter methylation was detected in 59/117 (50.4%) of patients with bladder cancer, and none of 37 (0%) controls. Methylation was significantly associated with advanced stage (T(2)-T(4)), high grade (G(3)), tumour recurrence and larger tumour size (\u003e 3 cm). In addition, methylation was associated with significantly worse survival and was an independent predictor of overall survival.\nCONCLUSION: Serum-based analysis of PCDH10 promoter methylation may represent a useful noninvasive biomarker of malignant behaviour and outcome in bladder cancer."}